Department of Cardiology, Fukuoka University School of Medicine, Jonan-ku, Fukuoka, Japan.
Clin Exp Hypertens. 2012;34(5):342-9. doi: 10.3109/10641963.2012.683912. Epub 2012 May 8.
Fifty-four patients were randomly divided into irbesartan and olmesartan groups. Blood pressure (BP) was significantly decreased in all patients at 12 weeks. In particular, BP in patients who initially received irbesartan showed significant reductions. The equality of variance of BP in the irbesartan group was significantly smaller than that in the olmesartan group at 12 weeks. Blood concentrations of adiponectin were significantly increased in the irbesartan group at 12 weeks. Log [pentraxin-3] in the irbesartan group were significantly decreased. In conclusion, the ability of irbesartan to reduce BP is comparable to that of olmesartan with equivalent safety.
54 名患者被随机分为厄贝沙坦组和奥美沙坦组。所有患者在 12 周时血压（BP）均显著降低。特别是，最初接受厄贝沙坦治疗的患者的 BP 显著降低。12 周时，厄贝沙坦组的 BP 方差均等性显著小于奥美沙坦组。12 周时，厄贝沙坦组的脂联素血浓度显著升高。厄贝沙坦组的 Log[五聚素-3]显著降低。总之，厄贝沙坦降低 BP 的能力与等效安全性的奥美沙坦相当。
